Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 31  |  Issue : 3  |  Page : 905-910

Myeloma immunotherapy


1 Department of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Hemodialysis Unit, Almahalla Alkobra Fever Hospital, Almahalla Alkobra, Egypt

Correspondence Address:
Amira M Elmasry
Almahalla Alkobra City, Elgharbia Governorate
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_29_17

Rights and Permissions

The objective of this study was to review the role of immunotherapy in treating multiple myeloma (MM). Medline databases (PubMed, Medscape, and ScienceDirect) and all related materials available on the internet from January 1993 to December 2016 were searched. The initial search presented 90 articles of which 29 met inclusion criteria. The articles studied the role of immunotherapy in treating MM. If the studies did not fulfi ll inclusion criteria, they were excluded. Study quality assessment included whether ethics approval was gained, eligibility criteria were specifi ed, appropriate controls were used, adequate information was provided, and whether defi ned assessment measures were undertaken. Each study was reviewed independently; the data obtained were rebuilt into a new language according to the need of the researcher and arranged into different topics through the article. All articles included in this review were human studies. The studies defi ne myeloma as a disorder of differentiated plasma cells. Understanding immune dysregulation in myeloma has led to development of new therapies. Immunotherapy is a promising treatment modality in the management of MM. Many novel immunotherapies such as immunomodulatory drugs, adoptive cell therapy, and monoclonal antibodies were reviewed. Basic research efforts toward better understanding of normal and missing immune surveillance in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many novel immunotherapy strategies such as immunomodulatory drugs, adoptive cell therapy, and monoclonal antibodies are currently under investigation in clinical trials.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed501    
    Printed4    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal